RE:RE:Also a benefit to be realized . . . .
I think Labs has a more international game plan. Also there is an overwhelming demand for injestible pharmaceuticals grade cannabis oils for the pharmaceuticals industry. Doctors and especially in emmerging markets want to prescribe this as treatment for pain management and other disorders. The beauty of alot of these countries is their medicine is usually covered through gov health care services. Regarding other forms of concentrates. I believe convinience products such as vapes will be a reliable market. Not every home grower and black market producer will be able to get a good market share. And they won't be able to replicate the safety and consistency of their product. Regarding margin: labs is able to get bulk wholesale amounts of cannabis and cannabis biproducts for an extremely cheap cost. Producers are announcing their ability to produce bud at a low cost per gram say 1-3$ well labs is able to buy the trim/ subpar and or regular cannabis for that or even cheaper than their cost to produce because the producers have no use for it. Now they can turn that into a high margin product to generate profits like we have already seen quarter over quarter. Regarding labor: labs saves a huge amount of money not growing cannabis. They reap the rewards of a reliable cpg model but don't have to put in the high cost to produce and process cannabis, pay for energy use of growing cannabis and all the other costs associated with production of cannabis. Also don't forget they don't deal with crop loss or other instabilities in their operation